

**YU-PING LEE, PHARM D**

Dr. Lee is a pharmacy resident at the Cleveland Clinic, specializing in infectious disease.

MORTON GOLDMAN, PHARM D

Dr. Goldman is the pharmaceutical care clinical manager in the Department of Pharmacy at the Cleveland Clinic.

DONALD G. VIDT, MD, EDITOR

The role of azole antifungal agents for systemic antifungal therapy

■ KEY POINTS:

Amphotericin B remains the first-line agent for serious fungal infections in most patients, including immunocompromised patients (eg, those with AIDS) and in central nervous system infections.

The overall prevalence of resistance to azole agents is low. The only exception is in AIDS patients, in whom resistance is much higher than in other populations, and is increasing.

Azole agents can increase the concentration of phenytoin, cisapride, oral glucose-lowering agents, warfarin, digoxin, terfenadine, astemizole, and cyclosporine, potentially leading to toxicity.

■ **ABSTRACT:** Although amphotericin B remains the cornerstone of antifungal drug therapy, fluconazole and itraconazole have been found useful for long-term maintenance or prophylactic regimens. This article reviews characteristics of fluconazole and itraconazole and compares them with ketoconazole and amphotericin B.

Ketoconazole, fluconazole, and itraconazole have not supplanted amphotericin B for managing most serious fungal infections, but they offer alternatives in a variety of unique situations. These drugs (the “azoles”) are becoming standard as antifungal prophylactic agents in transplant recipients and as long-term suppressive agents for cryptococcal meningitis in patients with acquired immunodeficiency syndrome (AIDS). Fluconazole may also be useful in treating AIDS-related candidemia. Itraconazole and ketoconazole are both effective for blastomycosis, histoplasmosis, and coccidiomycosis. The azoles are significantly less nephrotoxic than amphotericin B, but are not without side effects. They also demonstrate a number of significant drug interactions.

■ HISTORY OF THE AZOLES

Miconazole, the first systemic azole agent, was introduced in 1969. However, its toxicity, side effects (especially arrhythmia), and poor efficacy limit its use.

Ketoconazole, introduced in 1977, was the first oral azole agent. It is not active against *Aspergillus*, but otherwise shares a similar spectrum of action with amphotericin B.

Fluconazole was introduced in 1990 and quickly became popular



owing to its attractive pharmacokinetic and side-effect profiles and its availability in intravenous and oral formulations.

Itraconazole was introduced in 1992. It is active against *Aspergillus* and has fewer side effects than ketoconazole.

■ HOW THE AZOLES WORK

The azoles alter fungal membrane permeability by inhibiting fungal cytochrome P450 and C-14 α -demethylase^{1,2}—enzymes shared by humans. Fluconazole and itraconazole act more specifically on the fungal enzymes than ketoconazole does, and therefore cause less blockage of human steroid synthesis and fewer side effects.^{1,3}

■ PHARMACOKINETICS

Fluconazole is highly bioavailable; others less so

Over 90% of an oral dose of fluconazole reaches the blood stream, perhaps owing to its relatively high water solubility and low molecular weight. Neither food nor gastric pH affects fluconazole's absorption.

In contrast, oral doses of ketoconazole and itraconazole are less bioavailable, with 37% to 97% of ketoconazole and 70% of itraconazole reaching the blood stream. Giving these drugs with food enhances their systemic absorption, especially itraconazole. Gastric pH affects the absorption of both agents, with a lower pH allowing improved absorption.

Ketoconazole and itraconazole are highly protein-bound; fluconazole less so

Ketoconazole and itraconazole are highly bound to plasma proteins (98% and 99.8%, respectively), and therefore are not significantly dialyzable and achieve relatively low levels in the cerebrospinal fluid. Nevertheless, itraconazole has been reported effective in treating cryptococcal and coccidioidal meningitis, a paradox similar to that seen with amphotericin B.

Fluconazole is more hydrophilic and has a low degree of protein binding. It is therefore dialyzable, and patients need dosage adjust-

ment after dialysis. Fluconazole enters the cerebrospinal fluid easily, where concentrations reach 50% to 90% of the plasma concentration.

Ketoconazole, itraconazole are metabolized in the liver; fluconazole is excreted by the kidneys

Ketoconazole and itraconazole undergo extensive metabolism by the cytochrome P450 system in the liver (more than 30 metabolites of itraconazole have been reported).

Fluconazole, in contrast, is primarily excreted unchanged by the kidneys. Patients with renal insufficiency require dosage adjustments with fluconazole but not with itraconazole or ketoconazole.

■ SPECTRUM OF ACTIVITY

Ketoconazole, fluconazole, and itraconazole are all active in vitro against *Cryptococcus neoformans*, *Candida albicans*, *Coccidioides immitis*, *Histoplasma capsulatum*, *Blastomyces dermatitidis*, and *Paracoccidioides brasiliensis*. Both fluconazole and itraconazole—but not ketoconazole—are active against *Sporothrix schenckii*. Itraconazole is the only currently available azole agent that covers *Aspergillus*. Fluconazole is less active against *Candida glabrata* and inactive against *Candida krusei*.⁴

■ THERAPEUTIC ROLES

Amphotericin B still the drug of choice

Amphotericin B remains the drug of choice for serious systemic fungal infections (TABLE 1). It is also the first-line agent for serious fungal infections in immunocompromised patients (eg, those with AIDS) and central nervous system infections.⁵⁻⁷ In coccidioidomycosis meningitis, amphotericin B is often given intravenously and intrathecally.⁶

In studies in non-AIDS-related cryptococcal meningitis, adding flucytosine to amphotericin B boosted the cure rate and reduced the rates of treatment failure and relapse.^{8,9} However, for AIDS-related cryptococcal meningitis, amphotericin B is suggested by itself, since adding flucytosine has not been

Giving terfenadine or astemizole with itraconazole or ketoconazole is contraindicated because of the potential for serious cardiovascular events

shown to increase the survival rate or to decrease the relapse rate of infection.¹⁰

Ketoconazole

Ketoconazole is the drug of choice for *Malassezia furfur* infections.⁶ Other uses:

- In blastomycosis and coccidioidomycosis (high doses recommended).^{11,12}

- In histoplasmosis and paracoccidioidomycosis (in which its efficacy is comparable to that of itraconazole).^{4,13–16}

- As prophylaxis in neutropenic patients^{17–20} (although its role is not well defined, because its absorption is erratic).

- In severe recalcitrant cutaneous dermatophyte infections not responding to topical therapy or oral griseofulvin or in patients unable to take griseofulvin.²

Fluconazole

Fluconazole has no effect against *Aspergillus* or *C krusei*, and is not very potent against blastomycosis,^{21,22} chromoblastomycosis,²³ or *Penicillium marneffei*.²⁴ It has variable efficacy against *C glabrata*.

Candidal infections. Fluconazole is useful in several situations:

- As prophylaxis against candidal infections in bone-marrow transplant recipients, who receive cytotoxic chemotherapy or radiation therapy.^{25–28}

- In oropharyngeal and esophageal candidiasis (in which it is the drug of choice, and several studies evaluated it in patients with AIDS).^{29–32}

- In urinary candidiasis (drug of choice).^{33,34}

- In vaginal candidiasis (drug of choice).^{33,35–38}

- In systemic candidal infections (although fluconazole was as effective as amphotericin B for candidemia, the studies were limited to catheter-related infections or included patients treated with amphotericin B for prolonged periods before starting fluconazole).^{39–41}

Cryptococcal infections. Fluconazole is an

TABLE 1

ANTIMICROBIAL EFFECTIVENESS OF AZOLE AGENTS AND AMPHOTERICIN B

Type of infection	Amphotericin B	Ketoconazole	Fluconazole	Itraconazole
Aspergillosis	+++	0	0	++
Blastomycosis				
Immunocompetent patients	++++	+++	0 to +	+++
Immunosuppressed patients	++++	++ to +++	0 to +	+++
Candidiasis				
Blood	++++	+	+++	?
Oropharyngeal, esophageal	?	++	+++	+++
Urinary	?	?	+++	?
Vaginal	?	+++	+++	++ to +++
Prophylaxis	?	?	+++	?
Chromoblastomycosis	++	++	0 to +	+++
Coccidiomycosis				
Nonmeningitis	+++	+++	++	+++
Meningitis	+++	++ to +++	++ to +++	++ to +++
Cryptococcal				
Non-AIDS patients	++++	0	+++	?
AIDS patients	++++	0	++ to +++	++
Maintenance therapy	++	?	++ to +++	+++
Histoplasmosis	++++	+++	++	+++
Leishmaniasis	+++	++	?	++
<i>Malassezia furfur</i> infection	?	++ to +++	?	++ to +++
Neutropenic prophylaxis	+++	++ to +++	+++	++ to +++
Onychomycosis	?	+++	+++	+++
Paracoccidioidomycosis	+++	+++	?	+++
<i>Penicillium marneffei</i> infection	+ to ++	?	0 to +	+ to ++
Sporotrichosis	++	0	+ to ++	++

Scale:

0 Not effective
+ Less effective
++ Moderately effective
+++ Effective
++++ Very effective
? Not yet established

alternative to amphotericin B in clinically stable patients without AIDS who have cryptococcal infections. In one study, fluconazole was as effective as amphotericin B in treating cryptococcal meningitis, but it was associated with a higher mortality rate during the first 2 weeks of therapy.⁴² Cerebrospinal fluid cultures remained positive for *Cryptococcus* significantly longer with fluconazole than with amphotericin (40.6 days vs 15.6 days).⁴³

Prophylactic use. Prudent use in bone marrow transplant recipients is warranted,^{44–51} even though excessive use of fluconazole can lead to drug resistance: an increased emergence of *C krusei* and *C glabrata* infections



TABLE 2

ADVERSE REACTIONS TO AZOLE AGENTS

Frequency	Reactions		
	Ketoconazole	Fluconazole	Itraconazole
Very common (> 10%)	—	—	Nausea
Common (1–10%)	Abdominal pain	Abdominal pain	Abdominal pain
	Asymptomatic	Asymptomatic	Asymptomatic
	liver dysfunction (2–12%)	liver dysfunction (< 5%)	liver dysfunction (0.3–2.7%)
	Nausea	Diarrhea	Headache
	Pruritus	Headache	Rash
Less common (< 1%)	Vomiting	Nausea	Vomiting
		Skin rash	
		Vomiting	
	Bulging fontanelles	Dizziness	Anorexia
	Chills	Hypokalemia	Decreased libido
	Diarrhea	Pallor	Diarrhea
	Dizziness		Dizziness
	Fever		Edema
	Gynecomastia		Fatigue
	Headache		Fever
	Hemolytic anemia		Hypertension
	Impotence		Hypokalemia
	Leukopenia		Impotence
	Photophobia		Malaise
Rare	Somnolence		Pruritus
	Thrombocytopenia		Somnolence
	—	Severe hepatotoxicity	—

has been reported.^{44,45} Nevertheless, drug resistance has not been a major problem.

Itraconazole

Itraconazole can be used to treat pulmonary and extrapulmonary aspergillosis in patients who cannot tolerate amphotericin B, or for whom amphotericin B fails.⁵² Other uses are shown in **TABLE 1**. Some clinicians prefer itraconazole to ketoconazole because it has fewer side effects, even though it is more expensive.

Itraconazole has also been used for neutropenic prophylaxis. Failures, however, have been reported in bone marrow transplant and AIDS patients when serum concentrations were less than 250 ng/mL.^{53,54} This may be because of decreased itraconazole absorption due to changes in gastric pH.

Itraconazole is also effective in treating superficial dermatomycoses,⁵⁵ as it persists in the skin, nails, and hair follicles at therapeutic levels for weeks after discontinuation. However, whether it offers any significant advantage over ketoconazole, fluconazole, or clotrimazole for treating superficial infections remains unclear.

MICROBIAL RESISTANCE

The overall prevalence of resistance to azole agents is low.^{46,47,51} The only exception is in AIDS patients, in whom resistance is much higher than in other populations (33% vs 11%)—and increasing.⁵⁶ As mentioned above, resistant strains of *C. krusei* and *C. glabrata* have emerged with incremental use of fluconazole.^{45,57} Resistant strains of *C. neoformans* have been reported in AIDS populations.⁵⁸

Amphotericin B remains very active against many species, with no resistance by candidal species being reported.⁵⁹ The only organisms reported resistant to amphotericin B are *Pseudallescheria boydii* and *Trichosporon beigelii*.^{59–61}

Tests of antifungal susceptibility correlate poorly with clinical outcome; an exception may be in HIV patients with *Candida* infections.^{62,63}

ADVERSE DRUG REACTIONS

TABLE 2 summarizes adverse drug reactions associated with ketoconazole, fluconazole, and itraconazole. Endocrine effects such as gynecomastia, decreased libido, and impotence are more frequent with ketoconazole than with itraconazole or fluconazole, because of ketoconazole's less-specific binding to human steroids.⁴

Use in pregnancy. The Food and Drug Administration places ketoconazole, itraconazole, and fluconazole in category C (studies in animals have shown adverse effects on the fetus, but no adequate studies have been

performed in humans). Amphotericin B, in contrast, is in category B (no adverse effects on the fetus in animal studies; no adequate studies in humans).

In studies in rats and mice, itraconazole caused dose-related maternal toxicity, embryotoxicity, and teratogenicity at doses of 40 to 160 mg/kg/day. Therefore, it should be used in pregnancy only when its benefits outweigh its potential risks.⁵⁵

DRUG INTERACTIONS

Fluconazole and itraconazole have fewer drug interactions than does ketoconazole, because they are more selective for fungal than for human cytochrome P450 (TABLE 3).

Azole agents can increase the concentration of phenytoin, cisapride, oral glucose-lowering agents, warfarin, digoxin, terfenadine, astemizole, and cyclosporine, potentially leading to toxicity.⁶⁴ Giving terfenadine or astemizole with itraconazole or ketoconazole is contraindicated because of the potential for serious cardiovascular adverse events, including ventricular tachycardia, *torsade de pointes*, and sudden death.²

Rifampin, isoniazid, phenobarbital, carbamazepine, and phenytoin induce hepatic enzymes and can lower fluconazole or itraconazole concentrations, potentially resulting in treatment failure.⁶⁵

Classic Coca-Cola has been reported to increase the serum concentration of ketoconazole, and is used to counteract ketoconazole's compromised absorption in persons with high gastric pH,⁶⁶ and to boost its effect in AIDS patients and bone-marrow transplant recipients.

DOSAGE AND FORMULATION

The dosage and duration of antifungal therapy depend on the type of infection, the severity of disease, and the patient's immune status (TABLE 4). Ketoconazole and itraconazole are available only in oral form; fluconazole comes in both intravenous and oral forms.

Because fluconazole is mainly excreted by the kidneys, dosage adjustment in patients

TABLE 3

DRUG INTERACTIONS OF AZOLE AGENTS

Interaction	Ketoconazole	Fluconazole	Itraconazole
Azole agent increases the level or effect of these drugs:	Astemizole (+++) Cisapride (++) Corticosteroids (++) Cyclosporine (++) Oral sulfonylureas (++) Phenytoin (++) Terfenadine (+++) Theophylline (++)	Astemizole (++) Caffeine (+) Cyclosporine (+) Oral sulfonylureas (+) Phenytoin (++) Terfenadine (++) Theophylline (++) Warfarin (++) Zidovudine (+)	Astemizole (+++) Cisapride (++) Cyclosporine (++) Digoxin (+) Oral sulfonylureas (+) Phenytoin (++) Terfenadine (+++) Theophylline (++)
Azole agent decreases the level or effect of these drugs:	Theophylline* (++)	—	—
These drugs increase the level or effect of the azole agent:	Cimetidine (++) Classic Coca-Cola† (++)	Cimetidine (+)	Cimetidine (++)
These drugs decrease the level or effect of the azole agent:	Antacids (++) H ₂ antagonists (++) Isoniazid (++) Omeprazole (++) Rifabutin (++) Rifampin (++)	Carbamazepine (+) Isoniazid (+) Phenobarbital (+) Phenytoin (+) Rifabutin (+) Rifampin (+)	Antacids (++) Carbamazepine (++) H ₂ antagonists (++) Isoniazid (++) Omeprazole (++) Phenobarbital (++) Phenytoin (++) Rifabutin (++) Rifampin (++)

*Ketoconazole was reported to possibly alter the absorption of sustained-release theophylline dosage forms without altering the pharmacokinetic profile of theophylline; until additional information is available, patients receiving sustained-release theophylline should be observed for reduced theophylline response during ketoconazole administration.⁶⁵

†Classic Coca-Cola has been used to increase the systemic concentration of ketoconazole, especially in patients with high gastric pH (eg, with long-term use of omeprazole).⁶⁶

Scale: + minor interaction; ++ moderate interaction; +++ major interaction

with renal insufficiency is necessary. Patients with a creatinine clearance less than 50 mL/minute should receive 50% of the normal maintenance dose.

Giving itraconazole via nasogastric tube without clogging the tube is a challenge. Ong and Fobes⁶⁷ recommend dissolving itraconazole beads in cranberry juice to avoid this problem.

COST CONSIDERATIONS

Ketoconazole 400 mg costs \$2 to \$4; an equivalent oral dose of fluconazole costs approximately four times as much, itraconazole costs five times as much, and intravenous fluconazole costs 25 times as much—approximately \$100 for a 400-mg bag, wholesale, not counting administration fees.

Since fluconazole has high bioavailability, the same dose can be given orally instead of



TABLE 4

DOSAGE GUIDELINES FOR AZOLE AGENTS

Agent and infection	Dosage		Duration
Ketoconazole			
Systemic infections (including blastomycosis, histoplasmosis)	200–400 mg daily		Candidiasis: at least 1–2 weeks Other systemic mycoses: 6 months Chronic mucocutaneous candidiasis usually requires maintenance therapy
Recalcitrant dermatophyte infections	200–400 mg daily		4 weeks
Fluconazole			
Oropharyngeal candidiasis	Loading:	200 mg	14 days
	Maintenance:	100 mg daily	
Esophageal candidiasis	Loading:	200 mg	21 days
	Maintenance:	100 mg daily	
Systemic candidiasis	Loading:	400 mg	28 days
	Maintenance:	200 mg daily	
Acute cryptococcal meningitis	Loading:	400 mg	10–12 weeks after cerebrospinal fluid culture becomes negative
	Maintenance:	200 mg daily	
Chronic cryptococcal meningitis	200 mg daily		For life, in patient with HIV infection
Vaginal yeast infection	150 mg		One dose
Prevention of candidiasis in bone marrow transplant patients	400 mg daily		Start several days before the anticipated onset of neutropenia, continue for 7 days after the neutrophil count rises above 1000 cells/mm ³
Itraconazole			
Blastomycosis	200–400 mg daily		Variable
Histoplasmosis	200–400 mg daily		Variable
Aspergillosis	200–400 mg daily		Variable
Life-threatening infections	Loading:	200 mg three times a day for 3 days	At least 3 months and until active fungal infection has resolved
	Maintenance:	200–400 mg daily	

Since fluconazole has high bioavailability, the same dose can be given orally instead of intravenously

intravenously without compromising serum concentrations—at one fifth the cost. At 400 mg/day, switching to oral fluconazole would save \$78 per day or \$546 per week. At 200 mg/day, the oral form would save \$56 per day or \$392 per week.

For these reasons, we encourage using oral

fluconazole whenever possible. However, while intravenous fluconazole is rarely indicated, it may be appropriate in patients who are sedated or unconscious, cannot tolerate the oral form, have significant nausea and vomiting, or have ileus. ■

1. Sud IJ, Feingold DS. Mechanisms of action of the antimycotic imidazoles. *J Invest Dermatol* 1981; 76:438-441.
2. Sewester CS, Olin BR, Hebel SK, et al. Drug facts and comparisons. St Louis: Wolters Kluwer, 1995:355C-359F.
3. Bailey EM, Hrakovsky DJ, Pybak MJ. The triazole antifungal agents: a review of itraconazole and fluconazole. *Pharmacotherapy* 1990; 10:146-153.
4. Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. *N Eng J Med* 1994; 330:263-272.
5. Drugs for AIDS and associated infections. *Med Lett Drugs Ther* 1992; 34:14-16.
6. Mandell GL, Bennett JE, Dolin R. Principles and practice of infectious diseases 4th ed. New York: Churchill Livingstone, 1995.
7. Prata A. Treatment of kala-azar with amphotericin B. *Trans R Soc Trop Med Hyg* 1963; 57:266-268.
8. Bennett JE, Dismukes WE, Duma RJ, et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. *N Eng J Med* 1979; 301:126-131.
9. Dismukes WE, Cloud G, Gallis HA, et al. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. *N Eng J Med* 1987; 317:334-341.
10. Chuck SI, Sande MA. Infections with *Cryptococcus neoformans* in the acquired immunodeficiency syndrome. *N Eng J Med* 1989; 321:794-799.
11. Bradsher RW, Rice DC, Abernathy RS. Ketoconazole therapy for endemic blastomycosis. *Ann Intern Med* 1985; 103:872-879.
12. Graybill FR, Stevens DA, Galgiani JN, et al. Ketoconazole treatment of coccidioid meningitis. *Ann NY Acad Sci* 1988; 544:488-496.
13. Negróni R, Robles AM, Arechavala A, Tucule MA, Galimberti R. Ketoconazole in the treatment of paracoccidioidomycosis and histoplasmosis. *Rev Infect Dis* 1980; 2:643-649.
14. Drugs for AIDS and associated infections. *Med Lett Drugs Ther* 1991; 33:95-102.
15. Dismukes WE, Bradsher RW Jr, Cloud GC, et al. Itraconazole therapy for blastomycosis and histoplasmosis: NIAID Mycoses Study Group. *Am J Med* 1992; 93:489-497.
16. Drugs for AIDS and associated infections. *Med Lett Drugs Ther* 1991; 33:95-102.
17. Shepp DH, Klosterman A, Siegel MS, Meyers JD. Comparative trial of ketoconazole and nystatin for prevention of fungal infection in neutropenic patients treated in a protective environment. *J Infect Dis* 1985; 152:1257-1263.
18. Bodey GP. Azole antifungal agents. *Clin Infect Dis* 1992; 14(Suppl 1):S161-S169.
19. Hann IM, Prentice HG, Corringham R, et al. Ketoconazole versus nystatin plus amphotericin B for fungal prophylaxis in severely immunocompromised patients. *Lancet* 1982; 1:826-829.
20. Benhamou E, Hartmann O, Nogues C, Maraninchi D, Valteau D, Lemerle J. Does ketoconazole prevent fungal infection in children treated with high-dose chemotherapy and bone marrow transplantation? Results of a randomized placebo-controlled trial. *Bone Marrow Transplant* 1991; 7:127-131.
21. Pappas PG, Bradsher RW, Chapman SW, et al. Fluconazole in the treatment of blastomycosis [abstract]. In: Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago. Sep 29 to Oct 2, 1991. Washington, DC: American Society for Microbiology 1991:292.
22. Pappas PG, Bradsher RW, Chapman SW, et al. Treatment of blastomycosis with fluconazole: a pilot study. The National Institute of Allergy and Infectious Diseases Mycoses Study Group. *Clin Infect Dis* 1995; 20:267-271.
23. Diaz M, Negróni R, Montero-Gei F, et al. A pan-American 5-year study of fluconazole therapy for deep mycosis in the immunocompetent host. *Clin Infect Dis*. 1992; 14(suppl):568-576.
24. Supparatpinoy K, Nelson KE, Merz WG, et al. Response to antifungal therapy by human immunodeficiency virus-infected patients with disseminated *Penicillium marneffei* infections and in vitro susceptibilities of isolates from clinical specimens. *Antimicrob Agents Chemotherapy* 1993; 2407-2411.
25. Alangaden G, Chandrasekar PH, Bailey E, et al. Antifungal prophylaxis with low-dose fluconazole during bone marrow transplantation. *Bone Marrow Transplant* 1994; 14:919-924.
26. Wingard JR, Merz WG, Rinaldi MG, et al. Association of *Torulopsis glabrata* infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. *Antimicrob Agents Chemother* 1993; 37:1847-1849.
27. Akiyama H, Sakamaki H, Onozawa Y. Fluconazole prophylaxis in patients with leukemia [letter]. *Ann Intern Med* 1993; 119:951.
28. Goldman M, Pottage JC, Weaver DC. *Candida krusei* fungemia: report of four cases and review of the literature. *Medicine* 1993; 72:143-150.
29. Marchisio P, Principi N. Treatment of oropharyngeal candidiasis in HIV-infected children with oral fluconazole. *Eur J Clin Microbiol Infect Dis* 1994; 13:338-340.
30. Plettenberg A, Stoehr A, Hoffken G, et al. Fluconazole therapy of oral candidiasis in HIV-infected patients: results of a multicentre study. *Infection* 1994; 22:58-63.
31. Akova M, Akahn HE, Uzun O, et al. Efficacy of fluconazole in the treatment of upper gastrointestinal candidiasis in neutropenic patients with cancer: factors influencing the outcome. *Clin Infect Dis* 1994; 18:298-304.
32. Hernandez-Sampelayo T. Fluconazole versus ketoconazole in the treatment of oropharyngeal candidiasis in HIV-infected children. Multicentre Study Group. *Eur J Clin Microbiol Infect Dis* 1994; 13:340-344.
33. Product information: Diflucan, fluconazole, Roerig Division, New York, 1994.
34. Bozzette SA, Gordon RL, Yen A, et al. Biliary concentrations of fluconazole in a patient with candidal cholecystitis: case report. *Clin Infect Dis* 1992; 15:701-703.
35. Bramer KW, Feczko JM. Single-dose oral fluconazole in the treatment of vaginal candidiasis. *Ann NY Acad Sci* 1988; 544:561-563.
36. Multicentre Study Group. Treatment of vaginal candidiasis with a single oral dose of fluconazole. *Eur J Clin Microbiol Infect Dis* 1988; 7:364-367.
37. Osinusi BO, Rotowa NA. Fluconazole as single-dose treatment of vulvo-vaginal candidiasis. *Curr Ther Res* 1988; 43:1014-1018.
38. Phillips RJM, Watson SA, McKay FF. An open multicentre study of the efficacy and safety of a single dose of fluconazole 150 mg in the treatment of vaginal candidiasis in general practice. *Br J Clin Pract* 1990; 44:219-222.
39. Edwards JE Jr, Filler SG. Current strategies for treating invasive candidiasis: emphasis on infections in non-neutropenic patients. *Clin Infect Dis* 1992; 14(Suppl 1):S106-S113.
40. Rex JH, Bennett JE, Sugar AM, et al. Fluconazole vs amphotericin B for treatment of candidemia: results of a randomized multicenter trial [abstract]. In: program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, October 17-20, 1993. Washington DC: American Society for Microbiology, 1993:267.
41. Kauffman CA, Bradley SF, Ross SC, Weber DR. Hepatosplenic candidiasis: successful treatment with fluconazole. *Am J Med* 1991; 91:137-141.
42. Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. *N Eng J Med* 1992; 326:83-89.
43. Larsen RA, Leal MAE, Chan LS. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS: a randomized trial. *Ann Intern Med* 1990; 113:183-187.
44. Karyotakis NC, Dignani MC, Anaissie EJ. SCH 51048, a new antifungal triazole active against hematogenous *Candida krusei* infections in neutropenic mice. *Antimicrob Agents Chemother* 1995; 39:775-777.
45. Nguyen MH, Peacock JE, Morris AJ, et al. The changing face of candidemia: emergence of non-candida albicans species and antifungal resistance. *Am J Med* 1996; 100:617-623.
46. Dudley MN. Clinical pharmacology of fluconazole. *Pharmacotherapy* 1990; 10(Suppl):141-145.
47. Johnson L, Chrysanthou E, Petrini B, et al. Fluconazole failure in two cases of disseminated candidiasis. *Scand J Infect Dis* 1995; 27:421-424.
48. Laguna F, Rodriguez-Tudela JL, Enriquez A. Fungemia due to fluconazole-resistant *Candida albicans* in a patient with AIDS. *Clin Infect Dis* 1994; 19:542-543.
49. Newman SL, Flanigan TP, Fisher A, et al. Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS. *Clin Infect Dis* 1994; 19:684-686.

CLEVELAND CLINIC JOURNAL OF MEDICINE



Let us hear from you

Let us hear your opinions about the *Cleveland Clinic Journal of Medicine*. Do you like current articles and sections? What topics would you like to see covered and how can we make the *Journal* more useful to you?

E-mail: ccjm@cesmtp.ccf.org

WWW: <http://www.ccf.org/ed/ccjhome.htm>

Cleveland Clinic Journal of Medicine
The Cleveland Clinic Foundation, EE37
9500 Euclid Avenue
Cleveland, Ohio 44195

Phone: 216.444.2661 Fax: 216.444.9385



50. White A, Goetz MB. Azole-resistant *Candida albicans*: report of two cases of resistance to fluconazole and review. *Clin Infect Dis* 1994; 19:687-692.
51. Fulton P, Phillips P. Fluconazole resistance during suppressive therapy of AIDS-related thrush and esophagitis caused by *Candida albicans* [abstract]. International Conference on AIDS 1990; 6:239.
52. Product information: Sporanox, itraconazole, Janssen Pharmaceutical, Titusville, NJ, 1994.
53. Denning DW, Donnelly JP, Hellreigel KP, Ito J, Martino P, Van's Wout JW. Antifungal prophylactics during neutropenia or allogeneic bone marrow transplantation: What is the state of the art? *Chemotherapy* 1992; 38(Suppl 1):43-49.
54. Boogaerts MA, Verhoef GE, Zachée P, Demuyneck H, Verbist L, De Beule K. Antifungal prophylactics with itraconazole in prolonged neutropenia: Correlation with plasma levels. *Mycoses* 1989; 32(Suppl 1):103-108.
55. Gupta AK, Sauder DN, Shear NH. Antifungal agents: An overview. Part I & II. *J Am Acad Dermatol* 1994; 30:677-933.
56. Law D, Moore B, Wardle HM et al. High prevalence of antifungal resistance in *Candida spp* from patients with AIDS. *J Antimicrob Chemother* 1994; 34:659-668.
57. Powderly WG. Resistant candidiasis. *AIDS Research & Human Retroviruses* 1994; 10:925-929.
58. Paugam A, Dupouy-Camet J, Blanche P, Gangneux JP, Troute-Schaefer C, Sicard D. Increased fluconazole resistance of *Cryptococcus neoformans* isolated from a patient with AIDS and recurrent meningitis. *Clin Infect Dis* 1994; 19:975-976.
59. Still JM Jr, Lae EJ, Belcher KE, Spencer SA. A comparison of susceptibility to five antifungal agents of yeast cultures from burn patients. *Burns* 1995; 21:167-170.
60. Walsh M, White L, Atkinson K, Enno A. Fungal *Pseudallescheria boydii* lung infiltrates unresponsive to amphotericin B in leukaemic patients. Royal Newcastle Hospital, NSW. *Aust NZ J Med* 1992 22:265-268.
61. Walsh TJ, Melcher GP, Rinaldi MG, et al. *Trichosporon beigelii*, an emerging pathogen resistant to amphotericin B. *J Clin Microbiol* 1990; 28:1616-1622.
62. Bailly GG, Perry FM, Denning DW, Mandal BK. Management of candidiasis after failure of fluconazole in an HIV cohort. *AIDS* 1994; 8:787-92.
63. Moore CB, Law D, Ganguli LA, Keaney MGL, Denning DW. High prevalence of antifungal resistance in *Candida* in patients with AIDS. *J Antimicrob Chemother* 1994; 45:659-668.
64. Itraconazole. *Med Lett Drugs Ther* 1993; 35:7-9.
65. Murphy E. Ketoconazole-theophyllin interaction. *Irish Med J* 1987; 80:123.
66. Chin TWF, Loeb M, Fong IW. Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole. *Antimicrob Agents Chemother* 1995; 39:1671-1675.
67. Ong DL, Fobes LM. Administering itraconazole via nasogastric tube [letter]. *Am J Health-Syst Pharm* 1996; 53:1962.

ADDRESS REPRINT REQUESTS to Morton Goldman, PharmD, The Cleveland Clinic Foundation, 5107, 9500 Euclid Avenue, Cleveland, OH 44107.